Rocket


Overview
Financials
News + Filings
Key Docs
Ownership





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Legend Biotech Corp (LEGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 144 Form 144 - Report of proposed sale of securities:
08/23/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Proxy Statement",
"Notice of Annual General Meeting",
"Form of Proxy",
"Voting Card and Instructions for ADS Holders"
08/15/2023 6-K Quarterly results
Docs: "6-K",
"Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights"
07/20/2023 6-K Quarterly results
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI ®"
06/06/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/26/2023 F-3ASR Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
05/25/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI ®"
05/18/2023 6-K Quarterly results
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech Reports First Quarter 2023 Results and Recent Highlights"
05/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings"
05/10/2023 SC 13G/A FMR LLC reports a 10% stake in LEGEND BIOTECH CORP
05/08/2023 6-K Quarterly results
05/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/21/2023 144 Form 144 - Report of proposed sale of securities:
04/21/2023 6-K Quarterly results
04/19/2023 144 Form 144 - Report of proposed sale of securities:
04/19/2023 6-K Quarterly results
04/18/2023 6-K Quarterly results
04/14/2023 6-K Quarterly results
04/05/2023 144 Form 144 - Report of proposed sale of securities:
04/05/2023 144 Form 144 - Report of proposed sale of securities:
04/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH 6-K",
"Legend Biotech Establishes Strategic Advisory Board"
04/03/2023 144 Form 144 - Report of proposed sale of securities:
02/14/2023 SC 13G/A HILLHOUSE INVESTMENT MANAGEMENT, LTD. reports a 5.9% stake in Legend Biotech Corporation
02/14/2023 SC 13G/A Zhang Fangliang reports a 0.3% stake in Legend Biotech Corporation
02/14/2023 SC 13G/A AquaPoint L.P. reports a 0.1% stake in Legend Biotech Corporation
02/14/2023 SC 13G/A GenScript Biotech Corp reports a 52.1% stake in Legend Biotech Corporation
02/09/2023 SC 13G FMR LLC reports a 9.2% stake in LEGEND BIOTECH CORP
01/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K",
"Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI ® Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma"
01/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "LEGEND BIOTECH CORPORATION 6-K"
01/09/2023 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy